B-intervention	0	11	Accelerated
I-intervention	12	19	partial
I-intervention	20	26	breast
I-intervention	27	38	irradiation
O	39	44	using
O	45	54	intensity
O	54	55	-
O	55	64	modulated
O	65	77	radiotherapy
O	78	84	versus
B-control	85	90	whole
I-control	91	97	breast
I-control	98	109	irradiation
O	109	110	:
O	111	112	5
O	112	113	-
O	113	117	year
O	118	126	survival
O	127	135	analysis
O	136	138	of
O	139	140	a
O	141	146	phase
O	147	148	3
O	149	159	randomised
O	160	170	controlled
O	171	176	trial
O	176	177	.

O	178	189	Accelerated
O	190	197	partial
O	198	204	breast
O	205	216	irradiation
O	217	218	(
O	218	222	APBI
O	222	223	)
O	224	227	has
O	228	232	been
O	233	243	introduced
O	244	246	as
O	247	249	an
O	250	261	alternative
O	262	271	treatment
O	272	278	method
O	279	282	for
O	283	291	selected
O	292	300	patients
O	301	305	with
O	306	311	early
O	312	317	stage
O	318	324	breast
O	325	331	cancer
O	332	333	(
O	333	335	BC
O	335	336	)
O	336	337	.

O	338	347	Intensity
O	347	348	-
O	348	357	modulated
O	358	370	radiotherapy
O	371	372	(
O	372	376	IMRT
O	376	377	)
O	378	381	has
O	382	385	the
O	386	397	theoretical
O	398	407	advantage
O	408	410	of
O	411	412	a
O	413	420	further
O	421	429	increase
O	430	432	in
O	433	437	dose
O	438	448	conformity
O	449	457	compared
O	458	462	with
O	463	468	three
O	468	469	-
O	469	480	dimensional
O	481	491	techniques
O	491	492	,
O	493	497	with
O	498	502	more
O	503	509	normal
O	510	516	tissue
O	517	524	sparing
O	524	525	.

O	526	529	The
O	530	533	aim
O	534	536	of
O	537	541	this
O	542	552	randomised
O	553	558	trial
O	559	561	is
O	562	564	to
O	565	572	compare
O	573	576	the
O	577	582	local
O	583	593	recurrence
O	594	597	and
O	598	606	survival
O	607	609	of
O	610	614	APBI
O	615	620	using
O	621	624	the
O	625	629	IMRT
O	630	639	technique
O	640	645	after
O	646	652	breast
O	652	653	-
O	653	663	conserving
O	664	671	surgery
O	672	674	to
O	675	687	conventional
O	688	693	whole
O	693	694	-
O	694	700	breast
O	701	712	irradiation
O	713	714	(
O	714	717	WBI
O	717	718	)
O	719	721	in
O	722	727	early
O	728	733	stage
O	734	736	BC
O	736	737	.

O	738	742	This
O	743	748	study
O	749	752	was
O	753	762	performed
O	763	765	at
O	766	769	the
O	770	780	University
O	781	783	of
O	784	792	Florence
O	793	794	(
O	794	802	Florence
O	802	803	,
O	804	809	Italy
O	809	810	)
O	810	811	.

O	812	817	Women
O	818	822	aged
B-age	823	827	more
I-age	828	832	than
I-age	833	840	40years
B-eligibility	841	849	affected
I-eligibility	850	852	by
I-eligibility	853	858	early
I-eligibility	859	861	BC
I-eligibility	861	862	,
I-eligibility	863	867	with
I-eligibility	868	869	a
I-eligibility	870	877	maximum
I-eligibility	878	890	pathological
I-eligibility	891	897	tumour
I-eligibility	898	902	size
I-eligibility	903	905	of
I-eligibility	906	910	25mm
O	910	911	,
O	912	916	were
O	917	925	randomly
O	926	934	assigned
O	935	937	in
O	938	939	a
O	940	941	1
O	941	942	:
O	942	943	1
O	944	949	ratio
O	950	952	to
O	953	960	receive
O	961	967	either
O	968	971	WBI
O	972	974	or
O	975	979	APBI
O	980	985	using
O	986	990	IMRT
O	990	991	.

O	992	1000	Patients
O	1001	1003	in
O	1004	1007	the
O	1008	1012	APBI
O	1013	1016	arm
O	1017	1025	received
O	1026	1027	a
O	1028	1033	total
O	1034	1038	dose
O	1039	1041	of
O	1042	1044	30
O	1045	1047	Gy
O	1048	1050	to
O	1051	1054	the
O	1055	1061	tumour
O	1062	1065	bed
O	1066	1068	in
O	1069	1073	five
O	1074	1079	daily
O	1080	1089	fractions
O	1089	1090	.

O	1091	1094	The
O	1095	1098	WBI
O	1099	1102	arm
O	1103	1111	received
O	1112	1116	50Gy
O	1117	1119	in
O	1120	1122	25
O	1123	1132	fractions
O	1132	1133	,
O	1134	1142	followed
O	1143	1145	by
O	1146	1147	a
O	1148	1153	boost
O	1154	1156	on
O	1157	1160	the
O	1161	1167	tumour
O	1168	1171	bed
O	1172	1174	of
O	1175	1179	10Gy
O	1180	1182	in
O	1183	1187	five
O	1188	1197	fractions
O	1197	1198	.

O	1199	1202	The
O	1203	1210	primary
O	1211	1214	end
O	1214	1215	-
O	1215	1220	point
O	1221	1224	was
B-outcome-Measure	1225	1235	occurrence
I-outcome-Measure	1236	1238	of
I-outcome-Measure	1239	1250	ipsilateral
I-outcome-Measure	1251	1257	breast
I-outcome-Measure	1258	1264	tumour
I-outcome-Measure	1265	1276	recurrences
I-outcome-Measure	1277	1278	(
I-outcome-Measure	1278	1283	IBTRs
I-outcome-Measure	1283	1284	)
O	1284	1285	;
O	1286	1289	the
O	1290	1294	main
O	1295	1303	analysis
O	1304	1307	was
O	1308	1310	by
O	1311	1320	intention
O	1320	1321	-
O	1321	1323	to
O	1323	1324	-
O	1324	1329	treat
O	1329	1330	.

O	1331	1335	This
O	1336	1341	trial
O	1342	1344	is
O	1345	1355	registered
O	1356	1360	with
O	1361	1375	ClinicalTrials
O	1375	1376	.
O	1376	1379	gov
O	1379	1380	,
O	1381	1387	number
O	1388	1399	NCT02104895
O	1399	1400	.

O	1401	1402	A
O	1403	1408	total
O	1409	1411	of
B-total-participants	1412	1415	520
O	1416	1424	patients
O	1425	1429	were
O	1430	1440	randomised
O	1441	1442	(
B-control-participants	1442	1445	260
O	1446	1448	to
O	1449	1457	external
O	1458	1461	WBI
O	1462	1465	and
B-intervention-participants	1466	1469	260
O	1470	1472	to
O	1473	1477	APBI
O	1478	1482	with
O	1483	1487	IMRT
O	1487	1488	)
O	1489	1496	between
O	1497	1502	March
O	1503	1507	2005
O	1508	1511	and
O	1512	1516	June
O	1517	1521	2013
O	1521	1522	.

O	1523	1525	At
O	1526	1527	a
O	1528	1534	median
O	1535	1541	follow
O	1541	1542	-
O	1542	1544	up
O	1545	1547	of
O	1548	1549	5
O	1549	1550	.
O	1550	1551	0
O	1552	1557	years
O	1558	1559	(
O	1559	1572	Interquartile
O	1573	1578	Range
O	1579	1580	(
O	1580	1583	IQR
O	1583	1584	)
O	1585	1586	3
O	1586	1587	.
O	1587	1588	4
O	1588	1589	-
O	1589	1590	7
O	1590	1591	.
O	1591	1592	0
O	1592	1593	)
O	1593	1594	,
O	1595	1598	the
B-outcome	1599	1603	IBTR
I-outcome	1604	1608	rate
O	1609	1612	was
O	1613	1614	1
O	1614	1615	.
O	1615	1616	5
O	1616	1617	%
O	1618	1619	(
B-iv-bin-abs	1619	1624	three
O	1625	1630	cases
O	1630	1631	)
O	1632	1634	in
O	1635	1638	the
O	1639	1643	APBI
O	1644	1649	group
O	1650	1651	(
O	1651	1653	95
O	1653	1654	%
O	1655	1665	confidence
O	1666	1674	interval
O	1675	1676	(
O	1676	1678	CI
O	1678	1679	)
O	1680	1681	0
O	1681	1682	.
O	1682	1683	1
O	1683	1684	-
O	1684	1685	3
O	1685	1686	.
O	1686	1687	0
O	1687	1688	)
O	1689	1692	and
O	1693	1695	in
O	1696	1699	the
O	1700	1703	WBI
O	1704	1709	group
O	1710	1711	(
B-cv-bin-abs	1711	1716	three
O	1717	1722	cases
O	1722	1723	;
O	1724	1726	95
O	1726	1727	%
O	1728	1730	CI
O	1731	1732	0
O	1732	1733	.
O	1733	1734	0
O	1734	1735	-
O	1735	1736	2
O	1736	1737	.
O	1737	1738	8
O	1738	1739	)
O	1739	1740	.

O	1741	1743	No
O	1744	1755	significant
O	1756	1766	difference
O	1767	1774	emerged
O	1775	1782	between
O	1783	1786	the
O	1787	1790	two
O	1791	1797	groups
O	1798	1799	(
O	1799	1802	log
O	1803	1807	rank
O	1808	1812	test
O	1813	1814	p
O	1814	1815	=
O	1815	1816	0
O	1816	1817	.
O	1817	1819	86
O	1819	1820	)
O	1820	1821	.

O	1822	1824	We
O	1825	1835	identified
B-cv-bin-abs	1836	1841	seven
B-outcome	1842	1848	deaths
O	1849	1851	in
O	1852	1855	the
O	1856	1859	WBI
O	1860	1865	group
O	1866	1869	and
O	1870	1874	only
B-iv-bin-abs	1875	1878	one
O	1879	1881	in
O	1882	1885	the
O	1886	1890	APBI
O	1891	1896	group
O	1897	1898	(
O	1898	1899	p
O	1899	1900	=
O	1900	1901	0
O	1901	1902	.
O	1902	1905	057
O	1905	1906	)
O	1906	1907	.

O	1908	1911	The
B-outcome	1912	1913	5
I-outcome	1913	1914	-
I-outcome	1914	1918	year
I-outcome	1919	1926	overall
I-outcome	1927	1935	survival
O	1936	1939	was
B-cv-bin-percent	1940	1942	96
I-cv-bin-percent	1942	1943	.
I-cv-bin-percent	1943	1944	6
I-cv-bin-percent	1944	1945	%
O	1946	1949	for
O	1950	1953	the
O	1954	1957	WBI
O	1958	1963	group
O	1964	1967	and
B-iv-bin-percent	1968	1970	99
I-iv-bin-percent	1970	1971	.
I-iv-bin-percent	1971	1972	4
I-iv-bin-percent	1972	1973	%
O	1974	1977	for
O	1978	1981	the
O	1982	1986	APBI
O	1987	1992	group
O	1992	1993	.

O	1994	1997	The
O	1998	2002	APBI
O	2003	2008	group
O	2009	2018	presented
O	2019	2032	significantly
O	2033	2039	better
O	2040	2047	results
O	2048	2059	considering
B-outcome	2060	2065	acute
O	2066	2067	(
O	2067	2068	p
O	2068	2069	=
O	2069	2070	0
O	2070	2071	.
O	2071	2075	0001
O	2075	2076	)
O	2076	2077	,
B-outcome	2078	2082	late
O	2083	2084	(
O	2084	2085	p
O	2085	2086	=
O	2086	2087	0
O	2087	2088	.
O	2088	2091	004
O	2091	2092	)
O	2092	2093	,
O	2094	2097	and
B-outcome	2098	2106	cosmetic
I-outcome	2107	2114	outcome
O	2115	2116	(
O	2116	2117	p
O	2117	2118	=
O	2118	2119	0
O	2119	2120	.
O	2120	2123	045
O	2123	2124	)
O	2124	2125	.

O	2126	2128	To
O	2129	2132	our
O	2133	2142	knowledge
O	2142	2143	,
O	2144	2148	this
O	2149	2151	is
O	2152	2155	the
O	2156	2161	first
O	2162	2172	randomised
O	2173	2178	study
O	2179	2184	using
O	2185	2188	the
O	2189	2193	IMRT
O	2194	2203	technique
O	2204	2207	for
O	2208	2212	APBI
O	2213	2221	delivery
O	2221	2222	.

O	2223	2225	No
O	2226	2237	significant
O	2238	2248	difference
O	2249	2251	in
O	2252	2257	terms
O	2258	2260	of
O	2261	2265	IBTR
O	2266	2269	and
O	2270	2277	overall
O	2278	2286	survival
O	2287	2290	was
O	2291	2299	observed
O	2300	2307	between
O	2308	2311	the
O	2312	2315	two
O	2316	2320	arms
O	2320	2321	.

O	2322	2326	APBI
O	2327	2336	displayed
O	2337	2338	a
O	2339	2352	significantly
O	2353	2359	better
O	2360	2368	toxicity
O	2369	2376	profile
O	2376	2377	.
